These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22105611)

  • 1. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.
    Jonasch E; McCutcheon IE; Waguespack SG; Wen S; Davis DW; Smith LA; Tannir NM; Gombos DS; Fuller GN; Matin SF
    Ann Oncol; 2011 Dec; 22(12):2661-2666. PubMed ID: 22105611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
    Oudard S; Elaidi R; Brizard M; Le Rest C; Caillet V; Deveaux S; Benoit G; Corréas JM; Benoudiba F; David P; Gaudric A; Hammel P; Joly D; Timsit MO; Méjean A; Richard S
    Oncotarget; 2016 Dec; 7(51):85306-85317. PubMed ID: 27852035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
    Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
    Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease.
    Yuan G; Liu Q; Tong D; Liu G; Yi Y; Zhang J; Zhang Y; Wang LA; Wang L; Chen R; Guan Y; Yi X; Lan W; Jiang J
    Cancer Biol Ther; 2018; 19(9):766-772. PubMed ID: 29947576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease.
    Tsimafeyeu I
    J Cancer Res Ther; 2015; 11(4):920-2. PubMed ID: 26881543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
    Jonasch E; Donskov F; Iliopoulos O; Rathmell WK; Narayan VK; Maughan BL; Oudard S; Else T; Maranchie JK; Welsh SJ; Thamake S; Park EK; Perini RF; Linehan WM; Srinivasan R;
    N Engl J Med; 2021 Nov; 385(22):2036-2046. PubMed ID: 34818478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
    Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
    Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable response of CNS hemangioblastomas to Pazopanib in a single patient with von Hippel-Lindau disease: Case report.
    Taylor DG; Ilyas A; Mehta GU; Chen CJ; Schiff D; Oldfield EH; Asthagiri AR
    J Clin Neurosci; 2018 Apr; 50():154-156. PubMed ID: 29396065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of sunitinib in a 30-year-old woman with pancreatic neuroendocrine tumors associated with Von Hippel-Lindau syndrome.
    Wang W; Jiang CY; Wang HW
    J Clin Gastroenterol; 2015 Jan; 49(1):89-90. PubMed ID: 24921213
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
    Jimenez C; Cabanillas ME; Santarpia L; Jonasch E; Kyle KL; Lano EA; Matin SF; Nunez RF; Perrier ND; Phan A; Rich TA; Shah B; Williams MD; Waguespack SG
    J Clin Endocrinol Metab; 2009 Feb; 94(2):386-91. PubMed ID: 19017755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
    Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
    BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer.
    Stewart GD; Powles T; Van Neste C; Meynert A; O'Mahony F; Laird A; Deforce D; Van Nieuwerburgh F; Trooskens G; Van Criekinge W; De Meyer T; Harrison DJ
    Oncotarget; 2016 May; 7(18):25241-50. PubMed ID: 27029034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
    Motzer RJ; Michaelson MD; Redman BG; Hudes GR; Wilding G; Figlin RA; Ginsberg MS; Kim ST; Baum CM; DePrimo SE; Li JZ; Bello CL; Theuer CP; George DJ; Rini BI
    J Clin Oncol; 2006 Jan; 24(1):16-24. PubMed ID: 16330672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system].
    Zhou J; Li NY; Zhou XJ; Zhou HB; Wu B; Jiang SJ; Ma HH; Zhang RS
    Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):145-50. PubMed ID: 20450758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.
    Ansari J; Fatima A; Fernando K; Collins S; James ND; Porfiri E
    Oncol Rep; 2010 Aug; 24(2):507-10. PubMed ID: 20596640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of β2-Adrenergic Receptor Reduces Inflammation and Oxidative Stress in Clear Cell Renal Cell Carcinoma.
    Albiñana V; Recio-Poveda L; González-Peramato P; Martinez-Piñeiro L; Botella LM; Cuesta AM
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR; Leggas M
    Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease.
    Kobayashi A; Takahashi M; Imai H; Akiyama S; Sugiyama S; Komine K; Saijo K; Takahashi M; Takahashi S; Shirota H; Sato N; Fujishima F; Shuin T; Shimodaira H; Ishioka C
    Intern Med; 2016; 55(6):629-34. PubMed ID: 26984080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.